Age-dependent biphasic changes in ischemic sensitivity in the striatum of Huntington's disease R6/2 transgenic mice

Journal of Neurophysiology

Volumn 93, Issue 2, 2005, Pages 758-765

  Klapstein, Gloria J ^a   Levine, Michael S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGING; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE COURSE; EXCITATORY POSTSYNAPTIC POTENTIAL; HUNTINGTON CHOREA; HYPOXIA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; TRANSGENIC MOUSE; AGE; ANIMAL; CBA MOUSE; CELL HYPOXIA; COMPARATIVE STUDY; FEMALE; GENETICS; IN VITRO STUDY; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGE FACTORS; ANIMALS; CELL HYPOXIA; CORPUS STRIATUM; EXCITATORY POSTSYNAPTIC POTENTIALS; FEMALE; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED CBA; MICE, TRANSGENIC;

EID: 12544249143     PISSN: 00223077     EISSN: None     Source Type: Journal    
DOI: 10.1152/jn.00483.2004     Document Type: Article

References (58)

1. Beal MF, Brouillet E, Jenkins BG, Ferrante RJ, Kowall NW, Miller JM, Storey E, Srivastava R, Rosen BR, and Hyman BT. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13: 4181-4192, 1993.
2. Beal MF, Ferrante RJ, Swartz KJ, and Kowall NW. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J Neurosci 11: 1649-1659, 1991.
3. Brouillet E, Conde F, Beal MF, and Hantraye P. Replicating Huntington's disease phenotype in experimental animals. Prog Neurobiol 59: 427-468, 1999.
4. Brouillet E, Jenkins BG, Hyman BT, Ferrante RJ, Kowall NW, Srivastava R, Roy DS, Rosen BR, and Beal MF. Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem 60: 356-359, 1993.
5. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, and Beal MF. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 41: 646-653, 1997.
6. Calabresi P, Pisani A, Mercuri NB, and Bernardi G. On the mechanisms underlying hypoxia-induced membrane depolarization in striatal neurons. Brain 118: 1027-1038, 1995.
7. Centonze D, Marfia GA, Pisani A, Picconi B, Giacomini P, Bernardi G, and Calabresi P. Ionic mechanisms underlying differential vulnerability to ischemia in striatal neurons. Prog Neurobiol 63: 687-696, 2001.
8. Cepeda C, Ariano MA, Calvert CR, Flores-Hernandez J, Chandler SH, Leavitt BR, Hayden MR, and Levine MS. NMDA receptor function in mouse models of Huntington disease. J Neurosci Res 66: 525-539, 2001.
9. Cepeda C, Hurst RS, Calvert CR, Hernandez-Echeagaray E, Nguyen OK, Jocoy E, Christian LJ, Ariano MA, and Levine MS. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 23: 961-969, 2003.
10. Coyle JT and Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 263: 244-246, 1976.
11. Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, and Bates GP. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90: 537-548, 1997.
12. 2+/calmodulin-dependent proteins in R6/2 Huntington's disease mice. Neuroreport 13: 707-711, 2002.
13. Ekholm A, Katsura K, Kristian T, Liu M, Folbergrova J, and Siesjo BK. Coupling of cellular energy state and ion homeostasis during recovery following brain ischemia. Brain Res 604: 185-191, 1993.
14. Haddad MS and Cummings JL. Huntington's disease. Psychiatr Clin North Am 20: 791-807, 1997.
15. Hansson O, Castilho RF, Korhonen L, Lindholm D, Bates GP, and Brundin P. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. J Neurochem 78: 694-703, 2001a.
16. Hansson O, Guatteo E, Mercuri NB, Bernardi G, Li XJ, Castilho RF, and Brundin P. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur J Neurosci 14: 1492-1504, 2001b.
17. Hansson O, Petersn A, Leist M, Nicotera P, Castilho RF, and Brundin P. Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc Natl Acad Sci USA 96: 8727-8732, 1999.
18. Harms L, Meierkord H, Timm G, Pfeiffer L, and Ludolph AC. Decreased N-acetyl-aspartate/choline ratio and increased lactate in the frontal lobe of patients with Huntington's disease: a proton magnetic resonance spectroscopy study. J Neurol Neurosurg Psychiatry 62: 27-30, 1997.
19. Hurlbert MS, Zhou W, Wasmeier C, Kaddis FG, Hutton JC, and Freed CR. Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 48: 649-651, 1999.
20. Jenkins BG, Brouillet E, Chen YC, Storey E, Schulz JB, Kirschner P, Beal MF, and Rosen BR. Non-invasive neurochemical analysis of focal excitotoxic lesions in models of neurodegenerative illness using spectroscopic imaging. J Cereb Blood Flow Metab 16: 450-461, 1996.
21. Jenkins BG, Klivenyi P, Kustermann E, Andreassen OA, Ferrante RJ, Rosen BR, and Beal MF. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington's disease mice. J Neurochem 74: 2108-2119, 2000.
22. Jenkins BG, Koroshetz WJ, Beal MF, and Rosen BR. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 43: 2689-2695, 1993.
23. Jenkins BG, Rosas HD, Chen YC, Makabe T, Myers R, MacDonald M, Rosen BR, Beal MF, and Koroshetz WJ. 1H NMR spectroscopy studies of Huntington's disease: correlations with CAG repeat numbers. Neurology 50: 1357-1365, 1998.
24. Kim GW and Chan PH. Involvement of superoxide in excitotoxicity and DNA fragmentation in striatal vulnerability in mice after treatment with the mitochondrial toxin, 3-nitropropionic acid. J Cereb Blood Flow Metab 22: 798-809, 2002.
25. Klapstein GJ, Fisher RS, Zanjani H, Cepeda C, Jokel ES, Chesselet MF, and Levine MS. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J Neurophysiol 86: 2667-2677, 2001.
26. Klapstein GJ, Vietla S, Lieberman DN, Gray PA, Airaksinen MS, Thoenen H, Meyer M, and Mody I. Calbindin-D28k fails to protect hippocampal neurons against ischemia in spite of its cytoplasmic calcium buffering properties: evidence from calbindin-D28k knockout mice. Neuroscience 85: 361-373, 1998.
27. Koroshetz WJ, Jenkins BG, Rosen BR, and Beal MF. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 41: 160-165, 1997.
28. Kristian T. Metabolic stages, mitochondria and calcium in hypoxic/ischemic brain damage. Cell Calcium 36: 221-233, 2004.
29. Laforet GA, Sapp E, Chase K, McIntyre C, Boyce FM, Campbell M, Cadigan BA, Warzecki L, Tagle DA, Reddy PH, Cepeda C, Calvert CR, Jokel ES, Klapstein GJ, Ariano MA, Levine MS, DiFiglia M, and Aronin N. Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J Neurosci 21: 9112-9123, 2001.
30. Levine MS, Klapstein GJ, Koppel A, Gruen E, Cepeda C, Vargas ME, Jokel ES, Carpenter EM, Zanjani H, Hurst RS, Efstratiadis A, Zeitlin S, and Chesselet MF. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res 58: 515-532, 1999.
31. Lodi R, Schapira AH, Manners D, Styles P, Wood NW, Taylor DJ, and Warner TT. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol 48: 72-76, 2000.
32. Luesse HG, Schiefer J, Spruenken A, Puls C, Block F, and Kosinski CM. Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus. Behav Brain Res 126: 185-195, 2001.
33. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, and Bates GP. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 87: 493-506, 1996.
34. Marks JD, Bindokas VP, and Zhang XM. Maturation of vulnerability to excitotoxicity: intracellular mechanisms in cultured postnatal hippocampal neurons. Brain Res Dev Brain Res 124: 101-116, 2000.
35. McGeer EG and McGeer PL. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 263: 517-519, 1976.
36. Morton AJ and Leavens W. Mice transgenic for the human Huntington's disease mutation have reduced sensitivity to kainic acid toxicity. Brain Res Bull 52: 51-59, 2000.
37. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, and Greenamyre JT. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 5: 731-736, 2002.
38. Petersen A, Hansson O, Puschban Z, Sapp E, Romero N, Castilho RF, Sulzer D, Rice M, DiFiglia M, Przedborski S, and Brundin P. Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. Eur J Neurosci 14: 1425-1435, 2001.
39. Plamondon H, Blondeau N, Ileurteaux C, and Lazdunski M. Mutually protective actions of kainic acid epileptic preconditioning and sublethal global ischemia on hippocampal neuronal death: involvement of adenosine A1 receptors and K(ATP) channels. J Cereb Blood Flow Metab 19: 1296-1308, 1999.
40. Schiefer J, Alberty A, Dose T, Oliva S, Noth J, and Kosinski CM. Huntington's disease transgenic mice are resistant to global cerebral ischemia. Neurosci Lett 334: 99-102, 2002.
41. Schulz JB, Matthews RT, Klockgether T, Dichgans J, and Beal MF. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol Cell Biochem 174: 193-197, 1997.
42. Schurr A, Payne RS, Miller JJ, and Rigor BM. Brain lactate, not glucose, fuels the recovery of synaptic function from hypoxia upon reoxygenation: an in vitro study. Brain Res 744: 105-111, 1997.
43. Schurr A, Reid KH, Tseng MT, West C, and Rigor BM. Adaptation of adult brain tissue to anoxia and hypoxia in vitro. Brain Res 374: 244-248, 1986.
44. Schurr A and Rigor BM. The mechanism of neuronal resistance and adaptation to hypoxia. FEBS Lett 224: 4-8, 1987.
45. Sebastiao AM, de Mendonca A, Moreira T, and Ribeiro JA. Activation of synaptic NMDA receptors by action potential-dependent release of transmitter during hypoxia impairs recovery of synaptic transmission on reoxygenation. J Neurosci 21: 8564-8571, 2001.
46. Starling AJ, Chandler SH, Cepeda C, and Levine MS. Alterations in NMDA and magnesium sensitivity occur early in development in the R6/2 mouse model of Huntington's disease. Soc Neurosci Abstr 206.3, 2003.
47. Tabrizi SJ and Schapira AH. Secondary abnormalities of mitochondrial DNA associated with neurodegeneration. Biochem Soc Symp 66: 99-110, 1999.
48. Taga K, Patel PM, Drummond JC, Cole DJ, and Kelly PJ. Transient neuronal depolarization induces tolerance to subsequent forebrain ischemia in rats. Anesthesiology 87: 918-925, 1997.
49. Tanaka E, Yamamoto S, Kudo Y, Mihara S, and Higashi H. Mechanisms underlying the rapid depolarization produced by deprivation of oxygen and glucose in rat hippocampal CA1 neurons in vitro. J Neurophysiol 78: 891-902, 1997.
50. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72: 971-983, 1993.
51. Turmaine M, Raza A, Mahal A, Mangiarini L, Bates GP, and Davies SW. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci USA 97: 8093-8097, 2000.
52. Vannucci SJ, Mummery R, Hawkes RB, Rider CC, and Beesley PW. Hypoxia-ischemia induces a rapid elevation of ubiquitin conjugate levels and ubiquitin immunoreactivity in the immature rat brain. J Cereb Blood Flow Metab 18: 376-385, 1998.
53. Weih M, Bergk A, Isaev NK, Ruscher K, Megow D, Riepe M, Meisel A, Victorov IV, and Dirnagi U. Induction of ischemie tolerance in rat cortical neurons by 3- nitropropionic acid: chemical preconditioning [published erratum appears in Neurosci Lett 278: 194, 2000]. Neurosci Lett 272: 207-210, 1999.
54. Weih M, Bergk A, Isaev NK, Ruscher K, Megow D, Riepe M, Meisel A, Victorov IV, and Dirnagi U. Induction of ischemie tolerance in rat cortical neurons by 3- nitropropionic acid: chemical preconditioning [published erratum appears in Neurosci Lett 278: 194, 2000]. Neurosci Lett 272: 207-210, 1999.
55. Yager JY, Shuaib A, and Thornhill J. The effect of age on susceptibility to brain damage in a model of global hemispheric hypoxia-ischemia. Brain Res Dev Brain Res 93: 143-154, 1996.
56. Young RS, Petroff OA, Aquila WJ, Cheung A, and Gore JC. Hyperglycemia and the rate of lactic acid accumulation during cerebral ischemia in developing animals: in vivo proton MRS study. Biol Neonate 61: 235-242, 1992.
57. Zar JH. Biostatistical Analysis. Englewood Cliffs, NJ: Prentice-Hall, 1984.
58. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, and Raymond LA. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Neuron 33: 849-860, 2002.